AstraZeneca has high hopes for the in-development AZD9291, a treatment for lung cancer expected to bring in $3 billion a year at its peak, and the drugmaker is working with rival Roche to craft a blood test that can spot ideal patients for the therapy.
Horizon Discovery, which makes its money providing development expertise to drugmakers, has signed a deal with Otsuka Pharmaceutical to apply its technology to some early-phase treatments.
Medtronic is teaming up with LifeTech Scientific to manufacture and distribute cardiac devices for China's growing cardiovascular market.
Global CRO Icon has deepened its longstanding relationship with Cambridge University, agreeing to lead a class on pricing and market access for new drugs.
TransCelerate BioPharma, a nonprofit run by 19 of the world's largest drugmakers, formed two years ago to help Big Pharma share resources and stop wasting time and money on noncompetitive work. Now, the group is looking to create a novel platform to standardize how clinical trial sites communicate with sponsors, choosing contractor Cognizant to develop it.
The CRO unit of nonprofit researcher SRI International has paired up with NIH's National Institute of Allergy and Infectious Diseases, signing a $49 million contract to handle preclinical work on potential treatments for HIV.
Basilea Pharmaceutica ran into an FDA roadblock in its efforts to commercialize a new antibiotic, but the Swiss drug developer already has a green light in Europe, and it's tapping Quintiles' global marketing expertise to launch the treatment on its home continent.
In a deal that will build on their existing mutual relationship, Bristol-Myers Squibb and Ono Pharmaceutical have formed a pact to bring immunotherapies to market in Japan, South Korea and Taiwan.
An interesting development in this age of Irish-fueled tax inversion deals, the Mayo Clinic and Enterprise Ireland have begun a 5-year collaboration to advance med tech innovation.
Shire has signed a $225 million agreement to brighten its future in rare diseases, bolstering a major selling point for AbbVie as the two prepare for a $54.7 billion merger.